Physician profile
Scott Penney
NPI 1467812784
$75,495.76
in general payments reported to CMS, 2019-2025
11 companies · $43K in 2025
The $43K reported for 2025 was more than what 96% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.49 · 2022: $206 · 2023: $434 · 2024: $32K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $46K · Honoraria: $18K · Travel and Lodging: $9,126 · Food and Beverage: $2,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $45,500.00 |
| Honoraria | $17,787.50 |
| Travel and Lodging | $9,125.85 |
| Food and Beverage | $2,838.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fennec Pharmaceuticals, INC. | $74,701.57 | 2023-2025 | Pedmark, Fyarro |
| Sobi, INC | $242.96 | 2022-2023 | |
| Servier Pharmaceuticals LLC | $144.53 | 2023-2025 | |
| Y-Mabs Therapeutics, INC. | $117.42 | 2023 | Danyelza |
| Uswm, LLC | $97.08 | 2025 | Iwilfin |
| Jazz Pharmaceuticals INC. | $53.43 | 2022 | |
| Amgen INC. | $37.49 | 2019 | |
| United Therapeutics Corporation | $30.57 | 2022 | |
| Pfizer INC. | $28.34 | 2025 | |
| Pharming Healthcare, INC. | $22.22 | 2023 | Ruconest |
| Tempus Ai, INC | $20.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Penney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.